The U.S. federal health department plans to take action to reduce the use of antidepressants, as announced by Robert F. Kennedy Jr. This move targets selective serotonin reuptake inhibitors, a common type of antidepressant. Kennedy, who served as the Trump administration’s health secretary, voiced his concerns at a recent event hosted by the Make America Healthy Again Institute. He claims, without evidence, that these drugs may be linked to rising school shootings and withdrawal symptoms when patients stop taking them.
According to a press release from the Department of Health and Human Services (HHS), the goal is to “curb psychiatric overprescribing” and to encourage “deprescribing” when it’s safe to do so. Kennedy clarified that while psychiatric medications will still be available, they should be seen as just one option among many.
He emphasized, “If you are taking psychiatric medication, we are not telling you to stop. We want you and your clinician to have the right information to make informed decisions.”
A 2025 survey found that nearly 17% of Americans reported using antidepressants. Interestingly, a large portion of respondents opposed restricting access to these medications. This shows a significant divide in public opinion regarding mental health treatments.
Kennedy expressed a particular concern about the overuse of these medications among children. In recent communications, HHS has urged providers to consider non-medication alternatives for treating depression. These options include therapy, proper nutrition, exercise, and social support.
The aim is to ensure that treatment planning incorporates evidence-based non-drug interventions. According to a recent HHS letter, when it’s appropriate, doctors should evaluate patients’ symptoms, review medication effectiveness, and consider deprescribing.
The American Psychiatric Association (APA), which represents over 40,000 physicians, welcomed the focus on mental health. They support the administration’s plans to enhance research and training but caution against framing the issue solely as overprescribing. They believe that this perspective oversimplifies a complicated crisis and ignores critical factors like workforce shortages and limited access to care.
“Deprescribing alone won’t fix this issue,” the APA stated. Instead, they urge for a balanced approach where patients have access to comprehensive care based on their individual needs. The conversation around antidepressant use is becoming increasingly complex, reflecting broader societal issues within mental health care.
In today’s environment, it’s crucial to consider diverse treatment options and listen to patient feedback. Engaging in open dialogue about mental health can lead to better outcomes for everyone.
For more insights, check out the New York Times’ coverage of this topic.
